MY

Molly Yang

Head of Portfolio Management at NZ Growth Capital Partners

New Zealand

Overview 

Molly Yang is currently the Head of Portfolio Management at NZGCP, with a background in venture capital, private equity, corporate finance, and start-ups. She has held key roles in investment management, project management, and new business development, showcasing expertise in sectors such as digital health and biotechnology. Notable highlights of Molly's career include her leadership in managing portfolios at NZGCP and her diverse experience in roles such as Senior Portfolio Manager, Investment Manager, and Board Advisor across various organizations in the healthcare and investment industries.

Work Experience 

  • Director

    2024 - Current

    Mo & Associates Limited is a consultancy committed to empowering early-stage funds and startups by delivering tailored services that drive measurable success. The firm specialises in strategic advice, fund operations and management, and commercialisation support, all underpinned by a deep understanding of market opportunities and community needs.

  • Operating Partner

    2025

    Nexus Capital is a specialist private equity fund-of-funds manager approved for Active Investor Plus (AIP) investors, focused on building portfolios that provide access to premier private capital funds in New Zealand and Australia. As an Operating Partner, I play a key leadership role in designing and executing the fund’s strategy, structuring investments, engaging with investors, and overseeing reporting. My responsibility is to ensure that the fund aligns with both migrant investor expectations and government regulatory requirements, driving value for all stakeholders.

  • Commercial Mentor

    2024 - 2025

    I serve as a mentor for KiwiNet's Emerging Innovator Programme, which provides targeted support to early-career scientists poised to become New Zealand's future innovators.

  • Head of Portfolio Management

    2023 - 2024

    NZGCP is a New Zealand Government Fund which is invested through two vehicles, a $300 million Venture Capital Fund of funds and a $50 million angel seed Fund. I manage a diverse portfolio of technology companies, from seed stage to publicly listed, providing support and facilitating connections to drive their international growth. As a senior member of the investment team and a member of the investment committee, I play a key role in strategic decision-making.

  • Senior Portfolio Manager

    2022 - 2022

  • Investment Manager

    2015 - 2022

    I am primary responsible for managing angel fund investments and also supporting venture capital fund of funds activities and performance monitoring. My main roles include new investment opportunity screening, due diligence, deal execution, divestment and portfolio management.

  • Board Observer

    2024 - 2024

    The Clinician is a leading digital health company that helps healthcare organisations globally to create more connected, convenient and patient-centred care pathways.

  • Board Observer

    2020 - 2022

    A first-of-its-kind, cutting-edge tech company revolutionizing the world of insights with game-changing AI products. In August 2024, Yabble was sold to London AIM-listed market research company YouGov.

  • Board Observer

    2020 - 2022

    Core Schedule is the leading provider of a suite of cloud-based work roster tools for staff in emergency departments, hospitals, medical training programs, and urgent care clinics in New Zealand, Australia, and the United States.

  • Board Advisor

    2017 - 2019

    New Zealand's first Chinese-led angel fund, aims to invest in high growth Kiwi start-up companies, helping them make the most of opportunities in China. I assisted Zino defining investment strategy in NZ and established connection in the local eco-system.

  • Investment Consultant

    2014 - 2014

    Worked on the preparation of raising a venture capital co-fund between New Zealand and Taiwan focused on healthcare opportunities of benefit to child health, being the government funds as cornerstone investors.

  • Senior Associate

    2011 - 2013

    AlphaBridge Group is a boutique investment firm dedicated in investment into healthcare, biotechnology and medical device sectors in China. I was worked on deal sourcing / screening, investment documentation, due diligence, financial analysis and post-investment management, including reporting, monitoring performance, support portfolio companies for overseas development, financial control and corporate governance.

Articles About Molly

Relevant Websites